A phase II trial of the vitamin D analogue seocalcitol (EB1089) in patients with inoperable pancreatic cancer

British Journal of Cancer

Volumn 86, Issue 5, 2002, Pages 680-685

  Evans, T R J ^a   Colston, K W ^b   Lofts, F J ^c   Cunningham, D ^d   Anthoney, D A ^a   Gogas, H ^c   De Bono, J S ^a   Hamberg, K J ^e   Skov, T ^e   Mansi, J L ^c  

^a BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c ST GEORGE S HOSPITAL   (United Kingdom)

^d ROYAL MARSDEN HOSPITAL   (United Kingdom)

^e LEO PHARMA A S   (Denmark)

Author keywords

Hypercalcaemia; Pancreatic cancer; Vitamin D

Indexed keywords

SEOCALCITOL;

ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG INDUCED DISEASE; FEMALE; HUMAN; HYPERCALCEMIA; MALE; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; CALCITRIOL; CARCINOMA; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 18344365573     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600162     Document Type: Article

References (41)

1. Vitamin D-endocrine system
2. A phase II study of ifosfamide (IFOS) plus N-acetyl cysteine (NAC) in metastatic measurable pancreatic adenocarcinoma
3. Human colon cell line HT-29: Characterisation of 1, 25-dihydroxyvitamin D3 receptor and induction of differentiation by the hormone
4. 5-FU infusion with mitomycin C versus 5FU infusions with methyl CCNU in the treatment of advanced upper gastrointestinal cancer
5. Improvement in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomised trial
6. Staging of cancer of the pancreas
7. The integration of chemotherapy into a combined modality approach for cancer treatment: VI. Pancreatic adenocarcinoma
8. Phase II trial of gemcitabine (2, 2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas
9. 1, 25-Dihydroxyvitamin D3 and malignant melanoma: The presence of receptors and inhibitors of cell growth in culture
10. EB. (1089:) a new vitamin D analogue that inhibits the growth of breast cancer cells in vivo and in vitro
11. Vitamin D receptors and anti-proliferative effects of vitamin D derivatives in human pancreatic carcinoma cells in vivo and in vitro
12. Combination of a potent 20-epi vitamin D3 analogue (KH10060) with 9 cis-retinoic acid irreversibly inhibits clonal growth, decreases bcl-2 expression, and induces apoptosis in HL-60 leukaemic cells
13. The steroid and thyroid hormone receptor superfamily
14. A phase II study of continuous-infusion 5-fluorouracil with cisplatin and epirubicin in inoperable pancreatic cancer
15. Inhibition of human cancer cell growth by 1, 25-dihydroxyvitamin D3 metabolites
16. The determination of the number of patients required in a follow-up trial of a new chemotherapeutic agent
17. South West Oncology Group standard response criteria, endpoint definitions and toxicity criteria
18. A phase I study of the vitamin D analogue EB1089 in patients with advanced breast and colorectal cancer
19. 1 alpha, 25′-dihydroxyvitamin D3 inhibits the invasive potential of human breast cancer cells in vitro
20. EB 1089, a novel vitamin D analogue with strong antiproliferative and differentiation-inducing effects on target cells
21. Vitamin D derivatives in combination with 9-cis retinoic acid promote active cell death in breast cancer cells
22. EB 1089: A synthetic analogue of vitamin D, induces apoptosis in breast cancer cells in vivo and in vitro
23. Metabolism of the vitamin D analogue EB 1089: Identification of in vivo and in vitro liver metabolites and their biological activities
24. A controlled study of combined 1, 3-bis-(2-chlorethyi)-1-nitrosurea and 5-fluorouracil therapy for advanced gastric and pancreatic cancer
25. FAM chemotherapy prolongs survival in pancreatic cancer; quality of life is unimpaired
26. Inhibition of prostate cancer metastasis in vivo: A comparison of 1, 25-dihydroxyvitamin D (calcitriol) and EB 1089
27. Inhibition of tumour cell-induced angiogenesis by retinoids. 1, 25-dihydroxyvitamin D3 and their combination
28. Chemotherapy in pancreatic cancer: Results of a controlled, prospective, randomised, multicentre trial
29. Chemotherapy for gastrointestinal cancer
30. Membrane receptor for steroid hormones: A case for specific cell surface binding sites for vitamin D metabolites and estrogens
31. Vitamin D analogue EB1089-induced prostate regression is associated with increased gene expression of insulin-like growth factor binding proteins
32. Differing shapes of 1 alpha, 25-dihydroxyvitamin D3 function as ligands for the D-binding protein, nuclear receptor and membrane receptor: A status report
33. Chemotherapy for advanced pancreatic cancer. A comparison of 5-fluorouracil, adriamycin and mitomycin C (FAM) with 5-fluorouracil, streptozotocin and mitomycin C (FSM)
34. Chemotherapy prolongs survival in inoperable pancreatic carcinoma
35. Differential and antagonistic effects of 9-cis-retinoic acid and vitamin D analogues on pancreatic cancer cells in vitro
36. The role of the vitamin D endocrine system in health and disease
37. A phase II trial of gemcitabine in patients with 5-FU refractory pancreas cancer
38. Pancreatic cancer: The greatest oncological challenge
39. Phase II study of epirubicin in advanced adenocarcinoma of the pancreas
40. Activity of cisplatin in adenocarcinoma of the pancreas
41. Growth-inhibiting effects of vitamin D analogues and retinoids on human pancreatic cancer cells